Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30778915 | 0.85 | MAP2K1 (0.47) | ALDH1A1HPGDHSD17B10ABL1SOS1 | |
| SCHEMBL5734786 | 0.85 | MAP2K1 (0.47) | ALDH1A1HPGDHSD17B10ABL1SOS1 | |
| SCHEMBL31585831 | 0.82 | CA12 (0.50) | PTPN1ALDH1A1TSHRHPGDHSD17B10 | |
| SCHEMBL15326189 | 0.82 | CA12 (0.50) | PTPN1ALDH1A1TSHRHPGDHSD17B10 | |
| SCHEMBL112046 | 0.81 | CES2 (0.61) | ALDH1A1TSHRHPGDHSD17B10ABL1 | |
| SCHEMBL1277539 | 0.81 | CA12 (0.44) | PTPN1ALDH1A1TSHRHPGDHSD17B10 | |
| SCHEMBL4150684 | 0.81 | MAP2K2 (0.52) | ALDH1A1TSHRHPGDHSD17B10L3MBTL1 | |
| SCHEMBL1462096 | 0.79 | ABL1 (0.61) | ALDH1A1TSHRHPGDHSD17B10ABL1 | |
| SCHEMBL2060214 | 0.79 | CYP46A1 (0.53) | ALDH1A1TSHRHPGDHSD17B10ABL1 | |
| SCHEMBL12240241 | 0.79 | CA12 (0.43) | PTPN1ALDH1A1TSHRHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025026218-A1 | ARYLAMINE COMPOUND HAVING PROTEIN DEGRADATION EFFECT | 杭州中美华东制药有限公司 | 2025-02-06 | — | — | WO | disclosed |
| CN-119060053-A | Nuclear receptor binding SET structural domain protein 2/3 inhibitor, and pharmaceutical composition and application thereof | 深圳众格生物科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-08-08 | — | — | US | disclosed |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| WO-2024034123-A1 | PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND | アステラス製薬株式会社 | 2024-02-15 | — | — | WO | disclosed |
| WO-2024034657-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HETEROCYCLIC COMPOUND | アステラス製薬株式会社 | 2024-02-15 | — | — | WO | disclosed |
| WO-2024034591-A1 | HETEROCYCLIC COMPOUND FOR INHIBITING AND/OR INDUCING DEGRADATION OF KRAS PROTEIN | アステラス製薬株式会社 | 2024-02-15 | — | — | WO | disclosed |
| WO-2024019103-A1 | HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2024-01-25 | — | — | WO | disclosed |
| WO-2023171781-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2023-09-14 | — | — | WO | disclosed |
| CN-110678450-B | Isoxazole derivatives as nuclear receptor agonists and uses thereof | 日东制药株式会社 | 2023-06-20 | — | — | CN | disclosed |
| US-20060167065-A1 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| CN-1802187-A | Benzoxazinyl-amido cyclopentyl-heterocyclic modulators of chemokine receptors | MERCK & CO INC (US) | 2006-07-12 | — | — | CN | disclosed |
| US-20060069088-A1 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | MERCK SHARP & DOHME LLC | 2006-03-30 | — | — | US | disclosed |
| EP-1615699-A2 | BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS | Merck & Co., Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| EP-1542667-A2 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1501514-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004092124-A2 | BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004009558-A2 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS, THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASES CAUSED BY SUCH MUTATIONS | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2003093297-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167065-A1 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | UPF1, VHL, URB2 | PTPN1 4123/4885ALDH1A1 1816/4885TSHR 3379/4885 |
| US-20060069088-A1 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | CCR1, CCR2, CCRL2 | PTPN1 1207/4885ALDH1A1 2799/4885TSHR 501/4885 |
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | PTPN1 1301/4885ALDH1A1 1135/4885TSHR 545/4885 |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | PTPN1 1614/4885ALDH1A1 840/4885TSHR 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.